Transcriptional dysregulation in Huntington's disease: The role of histone deacetylases

Pharmacological Research

Volumn 100, Issue , 2015, Pages 157-169

  Sharma, Sorabh ^a   Taliyan, Rajeev ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

HDACs; Histone acetylation; Histone deacetylase inhibitors; Huntington's disease; Suberoylanilide hydroxamic acid; Transcriptional dysregulation

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE INHIBITOR; PLACEBO; SELISISTAT;

ACETYLATION; APOPTOSIS; CELL DEATH; COGNITION; CONTROLLED STUDY; DEACETYLATION; DEFENSE MECHANISM; DOUBLE BLIND PROCEDURE; DROSOPHILA; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HISTONE ACETYLATION; HISTOPATHOLOGY; HUMAN; HUNTINGTON CHOREA; MOTOR PERFORMANCE; NERVE CELL; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION INITIATION; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; HUNTINGTON DISEASE;

ANIMALS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HUNTINGTON DISEASE; TRANSCRIPTION, GENETIC;

EID: 84940053993     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.08.002     Document Type: Review

References (145)

1. Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is unstable on Huntington's disease chromosomes Cell 72 1993 971 983
2. J. Nasir, S.B. Floresco, J.R. O'Kusky, V.M. Diewert, J.M. Richman, J. Zeisler, and et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes Cell 81 5 1995 811 823
3. S. Zeitlin, J.P. Liu, D.L. Chapman, V.E. Papaioannou, and A. Efstratiadis Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue Nat. Genet. 11 2 1995 155 163
4. M. DiFiglia, E. Sapp, K.O. Chase, S.W. Davies, G.P. Bates, J.P. Vonsattel, and et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 277 5334 1997 1990 1993
5. M. Ravache, C. Weber, K. Mérienne, and Y. Trottier Transcriptional activation of REST by Sp1 in Huntington's disease models PLoS One 5 12 2010 e14311
6. Y. Sari Huntington's disease: from mutant huntingtin protein to neurotrophic factor therapy Int. J. Biomed. Sci. 7 2 2011 89 100
7. L. Moumné, S. Betuing, and J. Caboche Multiple aspects of gene dysregulation in Huntington's disease Front. Neurol. 4 2013 127
8. J.H. Cha Transcriptional dysregulation in Huntington's disease Trends Neurosci. 23 2000 387 392
9. K.R. Bowles, S.P. Brooks, S.B. Dunnett, and L. Jones Gene expression and behaviour in mouse models of HD Brain Res. Bull. 88 2012 276 284
10. T. Seredenina, and R. Luthi-Carter What have we learnt from gene expression profiles in Huntington's disease Neurobiol. Dis. 45 2012 83 98
11. G. Sadri-Vakili, B. Bouzou, C.L. Benn, M.O. Kim, P. Chawla, R.P. Overland, and et al. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models Hum. Mol. Genet. 16 11 2007 1293 1306
12. L.E. Pena-Altamira, E. Polazzi, and B. Monti Histone post-translational modifications in Huntington's and Parkinson's diseases Curr. Pharm. Des. 19 2013 1 8
13. S. Sharma, and R. Taliyan Targeting histone deacetylases: a novel approach in Parkinson's disease Parkinson's Dis. 2015 2015 1 11
14. C. Rouaux, N. Jokic, C. Mbebi, S. Boutillier, J.P. Loeffler, and A.L. Boutillier Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration EMBO J. 22 24 2003 6537 6549
15. E. Kontopoulos, J.D. Parvin, and M.B. Feany Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity Hum. Mol. Genet. 15 20 2006 3012 3023
16. S. Sharma, R. Taliyan, and S. Ramagiri Histone deacetylase inhibitor, trichostatin A, improves learning and memory in high-fat diet-induced cognitive deficits in mice J. Mol. Neurosci. 56 1 2015 1 11
17. S. Sharma, and R. Taliyan Synergistic effects of GSK-3β and HDAC inhibitors in intracerebroventricular streptozotocin-induced cognitive deficits in rats, Naunyn Schmiedeberg's Arch. Pharmacol. 388 3 2015 337 349
18. S. Sharma, R. Taliyan, and S. Singh Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioural abnormalities: modulation of histone deacetylase activity Behav. Brain Res. 291 2015 306 314
19. J.S. Steffan, L. Bodai, J. Pallos, M. Poelman, A. McCampbell, B.L. Apostol, and et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila Nature 413 6857 2001 739 743
20. K.N. McFarland, S. Das, T.T. Sun, D. Leyfer, E. Xia, G.R. Sangrey, and et al. Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease PLoS One 7 7 2012 e41423
21. A.J. de Ruijter, A.H. van Gennip, H.N. Caron, S. Kemp, and A.B. Van Kuilenburg Histone deacetylases (HDACs): characterization of the classical HDAC family Biochem. J. 370 2003 737 749
22. D. Mottet, and V. Castronovo Histone deacetylases: target enzymes for cancer therapy Clin. Exp. Metastasis 25 2008 183 189
23. A. Didonna, and P. Opal The promise and perils of HDAC inhibitors in neurodegeneration Ann. Clin. Trans. Neurol. 2 1 2015 79 101
24. Z.Y. Wang, Q.I.N. Wen, and Y.I. Fan Targeting histone deacetylases: perspectives for epigenetic-based therapy in cardio-cerebrovascular disease J. Geriatric Cardiol. 12 2015 153 164
25. R.S. Broide, J.M. Redwine, N. Aftahi, W. Young, F.E. Bloom, and C.J. Winrow Distribution of histone deacetylases 1-11 in the rat brain J. Mol. Neurosci. 31 2007 47 58
26. A.K. Lucio-Eterovic, M.A. Cortez, E.T. Valera, F.J. Motta, R.G. Queiroz, H.R. Machado, and et al. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas BMC Cancer 8 2008 1 10
27. S. Baltan, A. Bachleda, R.S. Morrison, and S.P. Murphy Expression of histone deacetylases in cellular compartments of the mouse brain and the effects of ischemia Trans. Stroke Res. 2 2011 411 423
28. C. Janssen, S. Schmalbach, S. Boeselt, A. Sarlette, R. Dengler, S. Petri, and et al. Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis J. Neuropathol. Exp. Neurol. 69 2010 573 581
29. E. Hu, Z. Chen, T. Fredrickson, Y. Zhu, R. Kirkpatrick, G.F. Zhang, and et al. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor J. Biol. Chem. 275 2000 15254 15264
30. C.M. Grozinger, C.A. Hassig, and S.L. Schreiber Three proteins define a class of human histone deacetylases related to yeast Hda1p Proc. Natl. Acad. Sci. U. S. A. 96 1999 4868 4873
31. T.A. Bolger, and T.P. Yao Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death J. Neurosci. 25 2005 9544 9553
32. N.M. Tsankova, O. Berton, W. Renthal, A. Kumar, R.L. Neve, and E.J. Nestler Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action Nat. Neurosci. 9 2006 519 525
33. C.L. Benn, R. Butler, L. Mariner, J. Nixon, H. Moffitt, M. Mielcarek, and et al. Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease PLoS One 4 6 2009 e5747
34. W. Zhou, K. Bercury, J. Cummiskey, N. Luong, J. Lebin, and C.R. Freed Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease J. Biol. Chem. 286 2011 14941 14951
35. B. Lang, T.M. Alrahbeni, D.S. Clair, D.H. Blackwood, C.D. International Schizophrenia Consortium McCaig, and et al. HDAC9 is implicated in schizophrenia and expressed specifically in post-mitotic neurons but not in adult neural stem cells Am. J. Stem Cells 1 1 2011 31 41
36. C.M. Southwood, M. Peppi, S. Dryden, M.A. Tainsky, and A. Gow Microtubule deacetylases, SirT2 and HDAC6, in the nervous system Neurochem. Res. 32 2007 187 195
37. H.Y. Kao, C.H. Lee, A. Komarov, C.C. Han, and R.M. Evans Isolation and characterization of mammalian HDAC10, a novel histone deacetylase J. Biol. Chem. 277 2002 187 193
38. E. Sidorova-Darmos, R.G. Wither, N. Shulyakova, C. Fisher, M. Ratnam, M. Aarts, and et al. Differential expression of sirtuin family members in the developing, adult, and aged rat brain Front. Aging Neurosci. 6 2014 1 20
39. L. Gao, M.A. Cueto, F. Asselbergs, and P. Atadja Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family J. Biol. Chem. 277 2002 25748 25755
40. L. Quinti, V. Chopra, D. Rotili, S. Valente, A. Amore, and G. Franci Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model PLoS Curr. 2010 RN1172
41. F.H. Bardai, V. Price, M. Zaayman, L. Wang, and S.R. D'Mello Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death J. Biol. Chem. 287 42 2012 35444 35453
42. M. Mielcarek, C.L. Benn, S.A. Franklin, D.L. Smith, B. Woodman, P.A. Marks, and et al. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease PLoS One 6 2011 e27746
43. H. Jia, J. Pallos, V. Jacques, A. Lau, B. Tang, A. Cooper, and et al. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease Neurobiol. Dis. 46 2012 351 361
44. M. Hoshino, K. Tagawa, T. Okuda, M. Murata, K. Oyanagi, N. Arai, and et al. Histone deacetylase activity is retained in primary neurons expressing mutant huntingtin protein J. Neurochem. 87 2003 257 267
45. H. Jeong, F. Then, T.J.J. Melia, J.R. Mazzulli, L. Cui, J.N. Savas, and et al. Acetylation targets mutant huntingtin to autophagosomes for degradation Cell 137 2009 60 72
46. F.H. Bardai, and S.R. D'Mello Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3 J. Neurosci. 31 2011 1746 1751
47. F.H. Bardai, P. Verma, C. Smith, V. Rawat, L. Wang, and S.R. D'Mello Disassociation of histone deacetylase-3 from normal huntingtin underlies mutant huntingtin neurotoxicity J. Neurosci. 33 29 2013 11833 11838
48. T. Mano, T. Suzuki, S. Tsuji, and A. Iwata Differential effect of HDAC3 on cytoplasmic and nuclear huntingtin aggregates PLoS One 9 11 2014 e111277
49. L. Moumné, K. Campbell, D. Howland, Y. Ouyang, and G.P. Bates Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease PLoS One 7 2012 e31080
50. M. Katsuno, H. Adachi, A. Kume, M. Li, Y. Nakagomi, H. Niwa, and et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy Neuron 35 2002 843 854
51. I.A. Klement, P.J. Skinner, M.D. Kaytor, H. Yi, S.M. Hersch, H.B. Clark, and et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice Cell 95 1998 41 53
52. R.K. Kalathur, M.A. Hernández-Prieto, and M.E. Futschik Huntington's disease and its therapeutic target genes: a global functional profile based on the HD Research Crossroads database BMC Neurol. 12 2012 47
53. M. Mielcarek, D. Zielonka, A. Carnemolla, J.T. Marcinkowski, and F. Guidez HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements Front. Cell. Neurosci. 9 2015 42
54. D. Zielonka, I. Piotrowska, J.T. Marcinkowski, and M. Mielcarek Skeletal muscle pathology in Huntington's disease Front. Physiol. 5 2014 380
55. D. Zielonka, I. Piotrowska, and M. Mielcarek Cardiac dysfunction in Huntington's disease Exp. Clin. Cardiol. 20 2014 2547 2554
56. M. Mielcarek, L. Inuabasi, M.K. Bondulich, T. Muller, G.F. Osborne, S.A. Franklin, and et al. Dysfunction of the CNS-heart axis in mouse models of Huntington's disease PLoS Genet. 10 2014 e1004550
57. M. Mielcarek, M.K. Bondulich, L. Inuabasi, S.A. Franklin, T. Muller, and G.P. Bates The Huntington's disease-related cardiomyopathy prevents a hypertrophic response in the R6/2 mouse model PLoS One 9 2014 e108961
58. H.H. Yeh, D. Young, J.G. Gelovani, A. Robinson, Y. Davidson, K. Herholz, and et al. Histone deacetylases class II and acetylated core histone immunohisto-chemistry in human brains with Huntington's disease Brain Res. 1504 2013 16 24
59. M. Mielcarek, C. Landles, A. Weiss, A. Bradaia, T. Seredenina, L. Inuabasi, and et al. HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration PLoS Biol. 11 2013 e1001717
60. A. Bobrowska, P. Paganetti, P. Matthias, and G.P. Bates Hdac6 knockout increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease PloS One 6 6 2011 e20696
61. F.A.M. Ahmed Histone deacetylases 4 (HDAC4) inhibitors: a promising treatment for Huntington's disease ACS Med. Chem. Lett. 4 2013 692 693
62. C. Dominguez, and I. Munoz-Sanjuan Foundation-directed therapeutic development in Huntington's disease J. Med. Chem. 57 2014 5479 5488
63. J. Yang, L. Chen, J. Yang, J. Ding, S. Li, and H. Wu MicroRNA-22 targeting CBP protects against myocardial ischemia-reperfusion injury through anti-apoptosis in rats Mol. Biol. Rep. 41 1 2014 555 561
64. S.T. Lee, K. Chu, and W.S. Im Altered microRNA regulation in Huntington's disease models Exp. Neurol. 227 1 2011 172 179
65. A. Jovicic, J.F. Zaldivar Jolissaint, R. Moser, F. Silva Santos Mde, and R. Luthi-Carter MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms PLoS One 8 1 2013 e54222
66. C. Zuccato, N. Belyaev, P. Conforti, L. Ooi, M. Tartari, E. Papadimou, and et al. Widespread disruption of repressor Element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease J. Neurosci. 27 2007 6972 6983
67. D. Seigneurin-Berny, A. Verdel, S. Curtet, C. Lemercier, J. Garin, S. Rousseaux, and et al. Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways Mol. Cell. Biol. 21 2001 8035 8044
68. Y. Kawaguchi, J.J. Kovacs, A. McLaurin, J.M. Vance, A. Ito, and T.P. Yao The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress Cell 115 2003 727 738
69. T. Hideshima, J.E. Bradner, J. Wong, D. Chauhan, P. Richardson, S.L. Schreiber, and et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumour activity in multiple myeloma Proc. Natl. Acad. Sci. U. S. A. 102 2005 8567 8572
70. C. Simoes-Pires, V. Zwick, A. Nurisso, E. Schenker, P.A. Carrupt, and M. Cuendet HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Mol. Neurodegener 8 2013 7 7
71. A. Iwata, B.E. Riley, J.A. Johnston, and R.R. Kopito HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin J. Biol. Chem. 280 2005 40282 40292
72. J.P. Dompierre, J.D. Godin, B.C. Charrin, F.P. Cordelières, S.J. King, S. Humbert, and et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation J. Neurosci. 27 2007 3571 3583
73. M. Dokmanovic, G. Perez, W. Xu, L. Ngo, C. Clarke, R.B. Parmigiani, and et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7 Mol. Cancer Ther. 6 2007 2525 2534
74. C. Ma, and S.R. D'Mello Neuroprotection by histone deacetylase-7 (HDAC7) occurs by inhibition of c-jun expression through a deacetylase-independent mechanism J. Biol. Chem. 286 6 2011 4819 4828
75. V.D. Longo, and B.K. Kennedy Sirtuins in aging and age-related disease Cell 126 2006 257 268
76. G. Ramadori, C.E. Lee, A.L. Bookout, S. Lee, K.W. Williams, J. Anderson, and et al. Brain SIRT1: anatomical distribution and regulation by energy availability J. Neurosci. 28 2008 9989 9996
77. M. Tanno, J. Sakamoto, T. Miura, K. Shimamoto, and Y. Horio Nucleocytoplasmic shuttling of the NAD-dependent histone deacetylases SIRT1 J. Biol. Chem. 282 2007 6823 6832
78. J.A. Parker, M. Arango, S. Abderrahmane, E. Lambert, C. Tourette, H. Catoire, and et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons Nat. Genet. 37 2005 349 350
79. M.A. Sorolla, C. Nierga, M.J. Rodriguez-Colman, G. Reverter-Branchat, A. Arenas, J. Tamarit, and et al. Sir2 is induced by oxidative stress in a yeast model of Huntington disease and its activation reduces protein aggregation Arch. Biochem. Biophys. 510 2011 27 34
80. D.J. Ho, N.Y. Calingasan, E. Wille, M. Dumont, and M.F. Beal Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease Exp. Neurol. 225 2010 74 84
81. H. Jeong, D.E. Cohen, L. Cui, A. Supinski, J.N. Savas, J.R. Mazzulli, and et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway Nat. Med. 18 2012 159 165
82. M. Jiang, J. Wang, J. Fu, L. Du, H. Jeong, T. West, L. Xiang, Q. Peng, Z. Hou, H. Cai, and et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets Nat. Med. 18 2012 153 158
83. M. Jiang, J. Zheng, Q. Peng, Z. Hou, J. Zhang, and S. Mori Sirtuin 1 activator SRT2104 protects Huntington's disease mice Ann. Clin. Transl. Neurol. 1 12 2014 1047 1052
84. M.R. Smith, A. Syed, T. Lukacsovich, J. Purcell, B.A. Barbaro, and S.A. Worthge A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease Hum. Mol. Genet. 23 11 2014 2995 3007
85. S.D. Sussmuth, S. Haider, G.B. Landwehrmeyer, R. Farmer, C. Frost, and G. Tripepi An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease Br. J. Clin. Pharmacol. 79 3 2015 465 476
86. J. Pallos, L. Bodai, T. Lukacsovich, J.M. Purcell, J.S. Steffan, L.M. Thompson, and et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease Hum. Mol. Genet. 17 2008 3767 3775
87. R. Luthi-Carter, D.M. Taylor, J. Pallos, E. Lambert, A. Amore, A. Parker, and et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis Proc. Natl. Acad. Sci. U. S. A. 107 2010 7927 7932
88. D.M. Taylor, U. Balabadra, Z. Xiang, B. Woodman, S. Meade, A. Amore, and et al. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase ACS Chem. Biol. 2011 540 546
89. V. Chopra, L. Quinti, J. Kim, L. Vollor, K.L. Narayanan, and C. Edgerly The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models Cell Rep. 2 6 2012 1492 1497
90. A. Bobrowska, G. Donmez, A. Weiss, L. Guarente, and G. Bates SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo PLoS One 7 2012 e34805
91. P.A. Marks, V.M. Richon, R. Breslow, and R.A. Rifkind Histone deacetylase inhibitors as new cancer drugs Curr. Opin. Oncol. 13 2001 477 483
92. L.M. Valor Transcription, epigenetics and ameliorative strategies in Huntington's disease: a genome-wide perspective Mol. Neurobiol. 51 2015 406 423
93. L.M. Valor Epigenetic based therapies in the preclinical and clinical treatment of Huntington's disease Int. J. Biochem. Cell Biol. 2015 [Epub ahead of print]
94. L.M. Valor, and D. Guiretti What's wrong with epigenetics in Huntington's disease Neuropharmacology 80 2014 103 114
95. S.G. Gray Targeting histone deacetylases for the treatment of Huntington's disease CNS Neurosci. Ther. 16 2010 348 361
96. S.G. Gray Targeting Huntington's disease through histone deacetylases Clin. Epigenet. 2 2011 257 277
97. P.A. Marks, V.M. Richon, T. Miller, and W.K. Kelly Histone deacetylase inhibitors Advances in Cancer Research 91 2004 Academic Press 137 168
98. A. Villar-Garea, and M. Esteller Histone deacetylase inhibitors: understanding a new wave of anticancer agents Int. J. Cancer 112 2004 171 178
99. J.A. Plumb, P.W. Finn, R.J. Williams, M.J. Bandara, M.R. Romero, C.J. Watkins, and et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101 Mol. Cancer Ther. 2 2003 21 28
100. M. Yoshida, M. Kijima, M. Akita, and T. Beppu Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A J. Biol. Chem. 265 1990 17174 17179
101. P.A. Marks, and R. Breslow Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nat. Biotechnol. 25 2007 84 90
102. D.M. Chuang, Y. Leng, Z. Marinova, H.J. Kim, and C.T. Chiu Multiple roles of HDAC inhibition in neurodegenerative conditions Trends Neurosci. 32 2009 591 601
103. J.M. Wagner, B. Hackanson, M. Lübbert, and M. Jung Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy Clin. Epigenet. 1 3-4 2010 117 136
104. D.R. Grayson, M. Kundakovic, and R.P. Sharma Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Mol. Pharmacol. 77 2010 126 135
105. W.S. Xu, R.B. Parmigiani, and P.A. Marks Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 26 2007 5541 5552
106. Q. Lu, Y.T. Yang, C.S. Chen, M. Davis, J.C. Byrd, M.R. Etherton, and et al. Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors J. Med. Chem. 47 2003 467 474
107. E.A. Thomas, G. Coppola, P.A. Desplats, B. Tang, E. Soragni, R. Burnett, and et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice Proc. Natl. Acad. Sci. U. S. A. 105 40 2008 15564 15569
108. R. Furumai, A. Matsuyama, N. Kobashi, K.H. Lee, M. Nishiyama, H. Nakajima, and et al. FK228 (Depsipeptide) as a natural prodrug that inhibits class i histone deacetylases Cancer Res. 62 2002 4916 4921
109. N. Khan, M. Jeffers, S. Kumar, C. Hackett, F. Boldog, N. Khramtsov, and et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors Biochem. J. 409 2008 581 589
110. C. Campas-Moya Romidepsin for the treatment of cutaneous T-cell lymphoma Drugs Today (Barc) 45 2009 787 795
111. S. Spange, T. Wagner, T. Heinzel, and O.H. Kramer Acetylation of non-histone proteinsmodulates cellular signalling atmultiple levels Int. J. Biochem. Cell Biol. 41 2009 185 198
112. I. Gregoretti, Y.M. Lee, and H.V. Goodson Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis J. Mol. Biol. 338 2004 17 31
113. J. Trapp, R. Meier, D. Hongwiset, M.U. Kassack, W. Sippl, and M. Jung Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins) ChemMedChem 2 2007 1419 1431
114. T.F. Outeiro, E. Kontopoulos, S.M. Altmann, I. Kufareva, K.E. Strathearn, A.M. Amore, and et al. Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease Science 317 2007 516 519
115. H. Hess-Stumpp, T.U. Bracker, D. Henderson, and O. Politz MS-275, a potent orally available inhibitor of histone deacetylases - the development of an anticancer agent Int. J. Biochem. Cell Biol. 39 2007 1388 1405
116. S.J. Haggarty, K.M. Koeller, J.C. Wong, C.M. Grozinger, and S.L. Schreiber Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation Proc. Natl. Acad. Sci. U. S. A. 100 2003 4389 4394
117. A. Vannini, C. Volpari, G. Filocamo, E.C. Casavola, M. Brunetti, D. Renzoni, and et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor Proc. Natl. Acad. Sci. U. S. A. 101 2004 15064 15069
118. S. Balasubramanian, J. Ramos, W. Luo, M. Sirisawad, E. Verner, and J.J. Buggy A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas Leukemia 22 2008 1026 1034
119. R.J. Ferrante, J.K. Kubilus, J. Lee, H. Ryu, A. Beesen, B. Zucker, and et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice J. Neurosci. 23 28 2003 9418 9427
120. E. Hockly, V.M. Richon, B. Woodman, D.L. Smith, X. Zhou, E. Rosa, and et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease Proc. Natl. Acad. Sci. U. S. A. 100 4 2003 2041 2046
121. G. Gardian, S.E. Browne, D.K. Choi, P. Klivenyi, J. Gregorio, J.K. Kubilus, and et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease J. Biol. Chem. 280 1 2005 556 563
122. H. Jia, R.J. Kast, J.S. Steffan, and E.A. Thomas Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems Hum. Mol. Genet. 21 24 2012 5280 5293
123. D. Zadori, A. Geisz, E. Vamos, L. Vecsei, and P. Klivenyi Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease Pharmacol. Biochem. Behav. 94 2009 148 153
124. A. Giralt, M. Puigdellívol, O. Carretón, P. Paoletti, J. Valero, A. Parra-Damas, and et al. Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity Hum. Mol. Genet. 21 6 2012 1203 1216
125. C.T. Chiu, G. Liu, P. Leeds, and D.M. Chuang Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease Neuropsychopharmacology 36 12 2011 2406 2421
126. A. McCampbell, A.A. Taye, L. Whitty, E. Penney, J.S. Steffan, and K.H. Fischbeck Histone deacetylase inhibitors reduce polyglutamine toxicity Proc. Natl. Acad. Sci. U. S. A. 98 26 2001 15179 15184
127. R.E. Hughes, R.S. Lo, C. Davis, A.D. Strand, C.L. Neal, J.M. Olson, and et al. Altered transcription in yeast expressing expanded polyglutamine Proc. Natl. Acad. Sci. U. S. A. 98 23 2001 13201 13206
128. J.M. Oliveira, S. Chen, S. Almeida, R. Riley, J. Gonçalves, C.R. Oliveira, and et al. Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors J. Neurosci. 26 43 2006 11174 11186
129. H. Ryu, J. Lee, B.A. Olofsson, A. Mwidau, A. Dedeoglu, M. Escudero, and et al. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway Proc. Natl. Acad. Sci. U. S. A. 100 2003 4281 4286
130. T. Hathorn, A. Snyder-Keller, and A. Messer Nicotinamide improves motor deficits and upregulates PGC-1alpha and BDNF gene expression in a mouse model of Huntington's disease Neurobiol. Dis. 41 2011 43 50
131. E.A. Bates, M. Victor, A.K. Jones, Y. Shi, and A.C. Hart Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity J. Neurosci. 26 10 2006 2830 2838
132. H. Jia, C.D. Morris, R.M. Williams, J.F. Loring, and E.A. Thomas HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation Proc. Natl. Acad. Sci. U. S. A. 112 1 2015 E56 E64
133. J. Chen, E. Wang, L. Galan, M. Huynh, P. Joshi, C. Cepeda, and et al. Effects of pimelic diphenylamide histone deacetylase inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse models of Hungtington's disease PLoS curr. 5 2013
134. M. Beconi, O. Aziz, K. Matthews, L. Moumne, C. O'Connell, D. Yates, and et al. Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in CNS Invivo PLoS One 7 9 2012 e44498
135. D.S. Bachman, I.J. Butler, and G.M. McKhann Long-term treatment of juvenile Huntington's chorea with dipropylacetic acid Neurology 27 1977 193 197
136. I. Pearce, K.W. Heathfield, and M.J. Pearce Valproate sodium in Huntington chorea Arch. Neurol. 34 5 1977 308 309
137. C. Saft, T. Lauter, P.H. Kraus, H. Przuntek, and J.E. Andrich Dose-dependent improvement of myoclonic hyperkinesia due to valproic acid in eight Huntington's disease patients: a case series BMC Neurol. 6 2006 1 6
138. S. Kereshi, R.E. Schlagenhauff, and K.S. Richardson Myoclonic and major seizures in early adult Huntington's chorea: case-report and electro-clinical findings Clin. Electroencephalogr. 11 2 1980 44 47
139. V.E. Grove Jr., J. Quintanilla, and G.T. DeVaney Improvement of Huntington's disease with olanzapine and valproate N. Engl. J. Med. 343 13 2000 973 974
140. E. Unti, S. Mazzucchi, L. Kiferle, U. Bonuccelli, and R. Ceravolo Q09 Valproic Acid for the treatment of aggressiveness in Huntington's disease: 1-year follow-up J. Neurol. Neurosurg. Psychiatry 83 2012 A57
141. P. Hogarth, L. Lovrecic, and D. Krainc Sodium phenylbutyrate in Huntington's disease: a dose-finding study Mov. Disord. 22 13 2007 1962 1964
142. J.D. Best, and N. Carey Epigenetic therapies for non-oncology indications Drug Discov. Today 15 2010 1008 1014
143. S.D. Süssmuth, G.B. Landwehrmeyer, S.J. Tabrizi, C. Andersen, M. DiBacco, G. Tripepi, and et al. Q02 A randomised, double-blind, placebo-controlled phase IB pharmacodynamic study with selisistat (SEN0014196) in HD patients J. Neurol. Neurosurg. Psychiatry 83 2012 A55
144. R. Reilmann, F. Squitieri, J. Priller, C. Saft, C. Mariotti, S. Suessmuth, and et al. Safety and tolerability of selisistat for the treatment of Huntington's disease: results from a randomized, double-blind, placebo-controlled phase II trial (S47. 004) Neurology 82 Suppl. (10) 2014 S47.004
145. J.E. Bolden, M.J. Peart, and R.W. Johnstone Anticancer activities of histone deacetylase inhibitors Nat. Rev. Drug Discov. 5 2006 769 784